SureTrader Advertisement PRTC
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 38
Posts 28,613
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
Wall Street Looks To Economic Data For Clues On The Fed
Yellen hints at summer rate hike Memorial Day marks the unofficial beginning of summer, but baseball and barbecues may have to take a back...
Bank of America Relaunches Sale of Credit-Card Issuer MBNA
Culligan International Explores a Sale
Correction to Microsoft Smartphone Article on Wednesday
Facebook and Microsoft To Build Fiber Optic Cable Across Atlantic
Silicon Valley Driverless-Car Startup Raises Fresh Capital
ADRs End Mostly Lower; Alibaba, Baidu Trade Actively
Thermo Fisher Scientific to Buy FEI for $4.2 Billion
Correction to Valeant CEO Article on April 21
Valeant Rejected Joint Takeover Approach From Takeda, TPG
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 72606 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist